Tablets and pellets are the most common oral solid dosage forms. Tablets are cost effectively prepared by compression processes. Pellets are further processed by filling into capsules. Tablets are a flexible dosage form as immediate release and extended release tablets are available just by changing the excipients. Both, tablets and pellets may be coated for further functionalization. For example to increase swallow-ability or provide an enteric protection. Shin-Etsu provides excipients to prepare
Film coatings of this type are now in widespread use throughout the world. Although drug properties are the key factor in medicinal formulations, the physical form or the finish of a preparation is also important. PHARMACOAT® and TYLOPUR® hypromellose are easy to use as a film coating material and give an excellent finish. It is very versatile, and is suitable for many applications in the design of film-coated tablet formulations. PHARMACOAT® and TYLOPUR® films have the tough and flexible characteristics of cellulose derivatives. Although hypromellose film is not brittle, as acrylic polymer is, addition of a plasticizer such as polyethylene glycol (PEG 6000) is effective when highly flexible film is required. When PHARMACOAT® and TYLOPUR® films are used for film coating, sometimes titanium dioxide or pigments, as well as talc can be added to provide a smooth and colorful film.
Taste masking by coating with enteric polymer and pore former
Taste making of bitter tasting drugs is a common issue in formulation development. Taste masking of fine granules is sometime a major challenge due to the delay in drug release and difficulty of the coating operation. You can use an aqueous coating using METOLOSE® SM-4 without a sticking problem and no delay of dissolution. If you require time release of API after lag time for 5-10 minutes after administration is a feature of the dissolution behavior of sugar coating and such coating is a suitable method for taste masking. Combination of PHARMACOAT® / TYLOPUR® and enteric coating material, such as Shin-Etsu AQOAT® can also be coated on a tablet for taste masking effect.
Aqueous fine particle coating with angled spray [A-044]
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
Direct compression of spray dried dispersion [A-072]
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Dry Coating Technique of Pellets with Shin-Etsu AQOAT® using Centrifugal Granulator [A-075]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Impact of process parameters to solid dispersion particles [A-071]
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
Optimized Spray Drying Formulation using Shin-Etsu AQOAT® (HPMCAS) Targeting a Drug Release in the Upper Small Intestine [A-074]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
Taste masking coating for quinine tablets [A-061]
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
Aqueous fine particle coating with angled spray [A-044]
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
Direct compression of spray dried dispersion [A-072]
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Dry Coating Technique of Pellets with Shin-Etsu AQOAT® using Centrifugal Granulator [A-075]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Impact of process parameters to solid dispersion particles [A-071]
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
Optimized Spray Drying Formulation using Shin-Etsu AQOAT® (HPMCAS) Targeting a Drug Release in the Upper Small Intestine [A-074]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
Taste masking coating for quinine tablets [A-061]
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
Aqueous fine particle coating with angled spray [A-044]
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
Direct compression of spray dried dispersion [A-072]
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Dry Coating Technique of Pellets with Shin-Etsu AQOAT® using Centrifugal Granulator [A-075]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Impact of process parameters to solid dispersion particles [A-071]
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
Optimized Spray Drying Formulation using Shin-Etsu AQOAT® (HPMCAS) Targeting a Drug Release in the Upper Small Intestine [A-074]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
Taste masking coating for quinine tablets [A-061]
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
Aqueous fine particle coating with angled spray [A-044]
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
Direct compression of spray dried dispersion [A-072]
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Impact of process parameters to solid dispersion particles [A-071]
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
Taste masking coating for quinine tablets [A-061]
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
Aqueous fine particle coating with angled spray [A-044]
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
Direct compression of spray dried dispersion [A-072]
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Impact of process parameters to solid dispersion particles [A-071]
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
Taste masking coating for quinine tablets [A-061]
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
Aqueous fine particle coating with angled spray [A-044]
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
Direct compression of spray dried dispersion [A-072]
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Impact of process parameters to solid dispersion particles [A-071]
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
Taste masking coating for quinine tablets [A-061]
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
An enteric coating agent is used to protect drugs from degradation by gastric acid or to protect gastric mucosa from irritating drugs. Thus, an enteric coating agent is insoluble in gastric juice, and it immediately dissolves when the enteric preparation transfers to the small intestine. HPMCP (hypromellose phthalate) and Shin-Etsu AQOAT® (hypromellose acetate succinate) were introduced into the market as an alternative for enteric coating.
3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
Aqueous fine particle coating with angled spray [A-044]
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
Direct compression of spray dried dispersion [A-072]
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Impact of process parameters to solid dispersion particles [A-071]
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
Taste masking coating for quinine tablets [A-061]
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
Aqueous fine particle coating with angled spray [A-044]
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
Direct compression of spray dried dispersion [A-072]
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Impact of process parameters to solid dispersion particles [A-071]
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
Taste masking coating for quinine tablets [A-061]
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
Aqueous fine particle coating with angled spray [A-044]
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
Direct compression of spray dried dispersion [A-072]
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Impact of process parameters to solid dispersion particles [A-071]
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
Taste masking coating for quinine tablets [A-061]
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
Shin-Etsu AQOAT® is a enteric polymer suitable for aqueous polymer coatings. The coating dispersion is prepared with the HPMCAS-“F” fine powder grades to ensure trouble-free rapid coating process. "Dry coating" is a unique technique in which the polymer powder is directly applied to tablets or granules and the powder layer coalesces to form a film quickly by curing. In 2000, a Japanese pharmaceutical company commercialized this technique using Shin-Etsu AQOAT® for the first time. This technique is applicable for both tablets and granules using a regular apparatus with a powder feeding system. Ask your sales representative for further information.
Aqueous fine particle coating with angled spray [A-044]
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
Direct compression of spray dried dispersion [A-072]
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Dry Coating Technique of Pellets with Shin-Etsu AQOAT® using Centrifugal Granulator [A-075]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Impact of process parameters to solid dispersion particles [A-071]
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
Optimized Spray Drying Formulation using Shin-Etsu AQOAT® (HPMCAS) Targeting a Drug Release in the Upper Small Intestine [A-074]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
Taste masking coating for quinine tablets [A-061]
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
Aqueous fine particle coating with angled spray [A-044]
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
Direct compression of spray dried dispersion [A-072]
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Dry Coating Technique of Pellets with Shin-Etsu AQOAT® using Centrifugal Granulator [A-075]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Impact of process parameters to solid dispersion particles [A-071]
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
Optimized Spray Drying Formulation using Shin-Etsu AQOAT® (HPMCAS) Targeting a Drug Release in the Upper Small Intestine [A-074]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
Taste masking coating for quinine tablets [A-061]
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
Aqueous fine particle coating with angled spray [A-044]
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
Direct compression of spray dried dispersion [A-072]
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Dry Coating Technique of Pellets with Shin-Etsu AQOAT® using Centrifugal Granulator [A-075]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Impact of process parameters to solid dispersion particles [A-071]
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
Optimized Spray Drying Formulation using Shin-Etsu AQOAT® (HPMCAS) Targeting a Drug Release in the Upper Small Intestine [A-074]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
Taste masking coating for quinine tablets [A-061]
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
When Shin-Etsu AQOAT® is fully neutralized (e.g. by ammonia), it dissolves completely in the coating media. In this case the “G” granular grades are applied and no surfactant for wetting of the HPMCAS is required, simplifying your formulation.
3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
Aqueous fine particle coating with angled spray [A-044]
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
Direct compression of spray dried dispersion [A-072]
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Impact of process parameters to solid dispersion particles [A-071]
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
Taste masking coating for quinine tablets [A-061]
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
Aqueous fine particle coating with angled spray [A-044]
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
Direct compression of spray dried dispersion [A-072]
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Impact of process parameters to solid dispersion particles [A-071]
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
Taste masking coating for quinine tablets [A-061]
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
3D printing tablets with Shin-Etsu AQOAT® (HPMCAS) [A-069]
Application of Shin-Etsu AQOAT® (HPMCAS) as a carrier in solid dispersion [A-028]
Application of Shin-Etsu AQOAT® (HPMCAS) in extended release (ER) matrix tablet formulation [A-070]
Aqueous based enteric formulation of Shin-Etsu AQOAT® (HPMCAS) containing amino acid as a stabilizer [A-049]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Coating parameters of a tablet batch size 5-100kg) [A-002]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Preparation of coating dispersion) [A-001]
Aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) (Using a small tabletop coating machine we coated tablet batch size of 300g) [A-006]
Aqueous enteric coating for lansoprazole using Shin-Etsu AQOAT® (HPMCAS) [A-059]
Aqueous enteric coating for soft gelatin capsule using Shin-Etsu AQOAT® (HPMCAS) [A-043]
Aqueous enteric coating for soft gelatin capsule with Shin-Etsu AQOAT® (HPMCAS) [A-062]
Aqueous enteric coating using Shin-Etsu AQOAT® (HPMCAS) for Mini-Tablets [A-053]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 1: solution and film properties [A-008]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 2: examples of coating applications [A-012]
Aqueous enteric coating with Shin-Etsu AQOAT® (HPMCAS): ammonia-neutralized method - part 3: stability of the coated preparations [A-013]
Aqueous fine particle coating with angled spray [A-044]
Aqueous formulation of Shin-Etsu AQOAT® (HPMCAS) containing an amino acid as stabilizer - comparison of formulation and process parameters on different coating equipment [A-055]
Comparative study of various coating methods with Shin-Etsu AQOAT® (HPMCAS) for pellets [A-060]
Comparison of mini-tablets enteric coating with Shin-Etsu AQOAT® (HPMCAS) using perforated pan or fluid bed coating equipment [A-056]
Concentration - viscosity curve of Shin-Etsu AQOAT® (HPMCAS) [A-064]
Direct compression of spray dried dispersion [A-072]
Dissolution behavior of coated fine particles by aqueous and solvent coating [A-045, H-013]
Effect of hot melt extrusion on the physicochemical properties of Shin-Etsu AQOAT® (HPMCAS) [A-017]
Effect of substitution of Shin-Etsu AQOAT® (HPMCAS) on dissolution profile of nifedipine solid dispersions (SD) prepared by Hot Melt Extrusion [A-032]
Enteric coating of hard gelatin capsules using Shin-Etsu AQOAT® (HPMCAS) [A-029]
Enteric coating of omeprazol granules using Shin-Etsu AQOAT® (HPMCAS) [A-031]
Enteric coating with Shin-Etsu AQOAT® (HPMCAS) by using water-ethanol solution [A-004]
Examples of aqueous dispersion coating using Shin-Etsu AQOAT® (HPMCAS) [A-003]
Impact of process parameters to solid dispersion particles [A-071]
Influence of alcohol on gastric resistance of Shin-Etsu AQOAT® (HPMCAS) [A-014]
IR spectrums of HPMCP and Shin-Etsu AQOAT® [H-017, A-054]
Mechanical properties of hot melt extruded amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-073]
Milling and downstream processing of hot melt extruded (HME) amorphous solid dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-067]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) (2) [A-047]
Minimum film formation temperature of Shin-Etsu AQOAT® (HPMCAS) [A-005]
Molecular weight of Shin-Etsu AQOAT® (HPMCAS) [A-007]
Nifedipine solid dispersion using Shin-Etsu AQOAT® - preparation by HME and downstream processing [A-051]
Partially neutralized coating technique using Shin-Etsu AQOAT® (HPMCAS) [A-037]
Scale-up of tablet enteric coating using the partially ammonia neutralized Shin-Etsu AQOAT® (HPMCAS) dispersion [A-068]
Solid dispersions (SD) using Shin-Etsu AQOAT® (HPMCAS) by holt melt extrusion [A-018]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in alkali solutions for cleaning media after coating operations [A-021]
Solubility of Shin-Etsu AQOAT® (HPMCAS) in mixed organic solvents [A-035]
Solution preparation of HPMCP and Shin-Etsu AQOAT® (HPMCAS) [H-019, A-058]
Stability of Shin-Etsu AQOAT® (HPMCAS) at high temperatures [A-010]
Taste masking coating for quinine tablets [A-061]
Taste masking coating using Shin-Etsu AQOAT® (HPMCAS) and PHARMACOAT® with controlled release [A-063, P-018]
Triacetin as an alternative plasticizer for aqueous dispersion with Shin-Etsu AQOAT® (HPMCAS) [A-057]
Sugar coating binder
METOLOSE® SB-4 is a hypromellose grade used as a binder for sugar coating instead of gelatin and gum arabic.
Dissolution behavior of various lower viscosity grades [P-014]
Film properties of HPMC and MC [G-002]
Film properties of low-viscosity grades cellulose derivatives [G-011]
Oxygen permeability of low-viscosity grade cellulose derivatives [G-016]
Solubility of HPMC and MC in organic solvents [M-004]
Taste masking for fine granules by METOLOSE® and an acrylic polymer [M-003]
Sustained release (matrix tablets)
Hydrophilic matrix systems designed with water-soluble polymers, such as hypromellose, were first introduced in the early 1970s. Hydrophilic matrix system have allowed more controllable and reproducible drug release by controlling the chemical and physical properties of the polymer. METOLOSE® SR and TYLOPUR® SR (hypromellose) is especially suitable for this application, and provides a genuine consistency in the final products.
Recommended products
Grades
Description
Pharmacopoeia
Origin
Recommendation
Knowledge Base
METOLOSE®
60SH´s
Hypromellose 2910, different viscosities 50-10000 mPas
PHARMACOAT®, METOLOSE® and TYLOPUR® can also be used as a binder for granulation. The fine particle size (average 50-70 μm) allows good mixture with the vehicle (lactose/cornstarch) and PHARMACOAT®, METOLOSE® and TYLOPUR® are effective for fluidized bed granulation and high shear mixer granulation (dry-blend).
One of the benefits of L-HPC is to resolve “capping” in immediate release formulations, which is a typical problem in the tableting process. Several reports have highlighted that capping is caused by a high residual die-wall pressure during the tableting process. L-HPC reduces the residual die-wall force and ejection force during the tableting process. For this application we recommend that you use LH-11. However using LH-21, 22 or NBD-020 also acceptable results when better flow is required.
Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
Super-high speed direct compression using L-HPC NBD [L-027]
Dissolution improvement for wet granulation (WG)
To accelerate API dissolution from immediate release tablets, a quick disintegration into fine particles by fast and strong swelling is preferred. LH-B1 featuring highest swelling rate and pressure among the L-HPC grades gives you the best result.
Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
Change of swelling performance of disintegrants after wet granulation [L-031]
Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
Influence of tablet shape on capping tendency [L-032]
Interaction with L-HPC and vitamins [L-038]
Minitablets using L-HPC [L-024]
Pellet extrusion - spheronizazion using L-HPC [L-011]
Pellets preparation by drug layering using L-HPC [L-015]
Rapid release from hard capsules using L-HPC as a filler [L-009]
Roller compaction using L-HPC - influence of re-processing [L-010]
Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
The effect of a glidant on L-HPC [L-029]
The effect of a glidant on L-HPC for dry granulation [L-030]
Twin screw granulation using L-HPC [L-028]
Water absorption of L-HPC [L-041]
Water binding capability of L-HPC in wet granulation [L-018]
Disintegration improvement for wet granulation (WG)
All L-HPC grades give a fast disintegration of immediate release tablets. However there are differences in swelling rate and pressure. The L-HPC B1 grade with highest swelling rate and pressure gives you the quickest disintegration when a formulation is processed by WG and compressed into tablets
Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
Change of swelling performance of disintegrants after wet granulation [L-031]
Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
Influence of tablet shape on capping tendency [L-032]
Interaction with L-HPC and vitamins [L-038]
Minitablets using L-HPC [L-024]
Pellet extrusion - spheronizazion using L-HPC [L-011]
Pellets preparation by drug layering using L-HPC [L-015]
Rapid release from hard capsules using L-HPC as a filler [L-009]
Roller compaction using L-HPC - influence of re-processing [L-010]
Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
The effect of a glidant on L-HPC [L-029]
The effect of a glidant on L-HPC for dry granulation [L-030]
Twin screw granulation using L-HPC [L-028]
Water absorption of L-HPC [L-041]
Water binding capability of L-HPC in wet granulation [L-018]
Binding for wet granulation (WG)
In wet granulation, L-HPC is beneficial in the powder blend to increase binding and compactibility. Among the L-HPC grades, LH-11 and LH-21 are two recommendations for wet granulated immediate release formulations.
Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
Super-high speed direct compression using L-HPC NBD [L-027]
Binding for roller compaction (RC)
Roller compaction is a dry granulation technique. The powder blend requires sufficient binding to form a stable ribbon and larger granules with less fine powders after the milling step. L-HPC NBD-grades are low-substituted hydroxypropyl cellulose and increase the binding properties of your roller compaction formulation. At the same time L-HPC acts as disintegrant ensuring the quick disintegration of your roller compacted IR formulation. Best performance in roller compaction give the compactibility optimized L-HPC NBD grades. LH-31/32 is suitable as well.
Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
Super-high speed direct compression using L-HPC NBD [L-027]
Dissolution improvement from drug layer
L-HPC enhances dissolution from a coated drug layer by its swelling properties. L-HPC 31 and 32 can also be used in powder layering the API, this can be carried out in a centrifugal coater using a PHARMACOAT® / TYLOPUR® binder solution.
Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
Super-high speed direct compression using L-HPC NBD [L-027]
Pellet extrusion
As well as tableting, L-HPC is also applicable for pellet extrusion. Micronized grades (typically LH-31) are best suited for this application because smaller particles can easily pass through the screen. L-HPC provides wet mass with a “buffer effect” where the wet mass accepts a wider range of water content. L-HPC plasticizes wet mass and shows greater productivity (extrusion speed and yield). The final pellets show quick disintegration and better friability compared with non-L-HPC formulations.
Application of L-HPC and PHARMACOAT® in twin screw granulation for continuous manufacturing [L-039]
Bilayer tablets using L-HPC and METOLOSE® SR [SR-005]
Change of swelling performance of disintegrants after wet granulation [L-031]
Comparative study of various L-HPC for Paracetamol 500 mg tablets - hydroxypropyl content [L-020]
Comparative study of various L-HPC for Paracetamol 500 mg tablets - internal addition and particle attributes [L-021]
Comparative study of various L-HPC for Paracetamol 500 mg tablets - particle attributes [L-019]
Comparative study of various L-HPC for Paracetamol 500 mg tablets - roller compaction [L-022]
Differences in wet granulation (WG) processing using L-HPC - internal vs external addition [L-012]
Effect of the added water quantity to the tablet properties at wet granulation process with L-HPC [L-014]
Influence of tablet shape on capping tendency [L-032]
Interaction with L-HPC and vitamins [L-038]
Minitablets using L-HPC [L-024]
Pellet extrusion - spheronizazion using L-HPC [L-011]
Pellets preparation by drug layering using L-HPC [L-015]
Rapid release from hard capsules using L-HPC as a filler [L-009]
Roller compaction using L-HPC - influence of re-processing [L-010]
Suitability of L-HPC and PHARAMCOAT® in twin screw granulation: significance and synergistic effect [L-040]
The effect of a glidant on L-HPC [L-029]
The effect of a glidant on L-HPC for dry granulation [L-030]
Twin screw granulation using L-HPC [L-028]
Water absorption of L-HPC [L-041]
Water binding capability of L-HPC in wet granulation [L-018]
Orally disintegrating tablets (ODT)
Orally disintegrating tablets (ODT) differ from traditional tablets in that they are designed to be dissolved in the oral cavity rather than swallowed whole. Shin-Etsu developed a co-processed excipient especially for the ODT application by direct compression. This excipient is named SmartEx®. NBD-022 is our second recommended product for this application as it has the quickest disintegration and a better feeling in the mouth than the other NBD grades.
Orally disintegrating tablets using L-HPC (NBD Grades) [L-016]
Super-high speed direct compression using L-HPC NBD [L-027]
Dispersible tablets
Dispersible tablets are defined as oral solid dosage forms that need to be first dispersed in water before being administered to the patients. This specific type of tablets is very interesting when looking into patient adherence, especially for heterogeneous patient populations like children or people facing swallowing issues. Dispersible tablets have several advantages as they can be produced by direct compression providing enhanced stability of drug products compared to liquid dosage forms. On the other hand, being homogeneously dispersed into a liquid, the palatability of a drug is improved. Therefore a typical characteristic of dispersible tablets is a rapid disintegration into fine particles in a liquid.
Palatability is related to the amount of insoluble material and its particle size. A recent publication highlights Shin-Etsu’s co-processed excipient SmartEx® as most palatable co-processed excipients for direct compression of dispersible tablets (Dziemidowicz, K.; Lopez, F.L.; Bowles, B.J.; Edwards, A.J.; Ernest, T.B.; Orlu, M.; Tuleu, C. Co-Processed Excipients for Dispersible Tablets—Part 2: Patient Acceptability. AAPS PharmSciTech 2018, 19, 2646–2657, doi:10.1208/s12249-018-1104-2).
In case the particles needs to be granulated or lyophilized, low viscosity hypromellose PHARMACOAT® or TYLOPUR®, as well as low-substituted hydroxypropyl cellulose (L-HPC NBD grades) are suitable.
